Aurinia Pharmaceuticals
AUPH
145 hedge funds and large institutions have $806M invested in Aurinia Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 55 increasing their positions, 42 reducing their positions, and 22 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 42
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
0% more funds holding
Funds holding: 145 → 145 (0)
4% less call options, than puts
Call options by funds: $43.2M | Put options by funds: $44.9M
5.45% less ownership
Funds ownership: 51.47% → 46.02% (-5.5%)
15% less capital invested
Capital invested by funds: $948M → $806M (-$142M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.8M |
| 2 |
Morgan Stanley
New York
|
+$10M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$9.8M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$5.52M |
| 5 |
FAM
Fred Alger Management
New York
|
+$5.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$33.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$29.2M |
| 3 |
HM
HealthCor Management
New York
|
-$28.2M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$22.8M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$14.7M |
AUPH Hedge Fund Activity: Q4 2020 in Review
145 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2020, worth a combined $806M — down 15% from $948M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AUPH positions and 22 closed out — a net gain of 1 holder — while 55 added to existing stakes and 42 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $12.8M. The largest seller was Great Point Partners, cutting an estimated $33.6M.
- 145 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $806M of Aurinia Pharmaceuticals stock for Q4 2020, down 15% quarter-over-quarter.
- 23 funds opened new Aurinia Pharmaceuticals positions in Q4 2020 and 22 closed out, a net change of +1 holder.
- The largest Aurinia Pharmaceuticals buyer in Q4 2020 was Fidelity Investments, an estimated $12.8M added.
- The largest Aurinia Pharmaceuticals seller in Q4 2020 was Great Point Partners, an estimated $33.6M sold.
Based on aggregated 13F filings for Q4 2020.